Two recent studies looked at changes in colorectal cancer (CRC) incidence over time, one in U.S. ... Rates of colorectal cancer (CRC) are increasing in adults younger than age 50 years in both the United States and Europe, according to two recent studies.
To assess the long-term detection rates with FIT for advanced adenoma and colorectal cancer by anatomical location, researchers conducted a population-based, organized screening program in Italy among patients ages ... invasive [colorectal cancer] and
According the American Cancer Society's Colorectal Cancer Survivorship Care Guidelines published in 2015, a history and physical examination should be performed every 3 to 6 months for the first 2 ... After treatment for stages 1, 2, or 3 colorectal
Black patients were more likely than white patients to be diagnosed with colorectal cancer between screening colonoscopies, a recent study found. ... Further research is needed, including about the quality of colorectal cancer screening for black
Results of a screening colonoscopy 4 years ago were normal. There is no family history of colorectal cancer. ... It is associated with the near-universal presence of gastric fundic gland polyposis, duodenal adenomas, and a personal or family history of
To evaluate the association of primary care clinic appointment time with clinician ordering and patient completion of breast and colorectal cancer screening, researchers conducted a retrospective study of 33 primary care ... Among the 33,468 patients
The accuracy of fecal immunochemical testing (FIT) for colorectal cancer screening does not appear to be affected by use of oral anticoagulants or aspirin/NSAIDs, according to a recent study. ... Researchers in the Netherlands performed a systematic
Patient navigation for the follow-up of abnormal results on cancer screening tests costs an additional $275 per patient (95% CI, $260 to $290 per patient).
Compared to the general Swiss population, patients with IBD had no increased risk for malignancy overall (standardized incidence ratio, 0.93; 95% CI, 0.72 to 1.18) or colorectal cancer ... The study authors noted limitations, such as the fact that
Regorafenib, a kinase inhibitor, works by blocking enzymes that promote cancer growth, including those in the vascular endothelial growth factor pathway. ... The drug is also approved to treat colorectal cancer and gastrointestinal stromal tumors that